CENTOGENE N.V. (CNTG): Price and Financial Metrics


CENTOGENE N.V. (CNTG): $11.33

-0.03 (-0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNTG POWR Grades


  • CNTG scores best on the Growth dimension, with a Growth rank ahead of 95.51% of US stocks.
  • CNTG's strongest trending metric is Growth; it's been moving up over the last 31 weeks.
  • CNTG ranks lowest in Momentum; there it ranks in the 16th percentile.

CNTG Stock Summary

  • With a one year PEG ratio of 3.46, Centogene NV is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 14.4% of US stocks.
  • CNTG's went public 1.73 years ago, making it older than merely 2.2% of listed US stocks we're tracking.
  • As for revenue growth, note that CNTG's revenue has grown 245.65% over the past 12 months; that beats the revenue growth of 97.12% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Centogene NV are SRAX, LOGC, ARDX, VSTM, and ASPU.
  • Visit CNTG's SEC page to see the company's official filings. To visit the company's web site, go to www.centogene.com.

CNTG Price Target

For more insight on analysts targets of CNTG, see our CNTG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.79 Average Broker Recommendation 1.1 (Strong Buy)

CNTG Stock Price Chart Interactive Chart >

Price chart for CNTG

CNTG Price/Volume Stats

Current price $11.33 52-week high $14.79
Prev. close $11.36 52-week low $8.61
Day low $11.20 Volume 18,900
Day high $11.67 Avg. volume 71,045
50-day MA $10.55 Dividend yield N/A
200-day MA $11.33 Market Cap 225.03M

CENTOGENE N.V. (CNTG) Company Bio


Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.


CNTG Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTG Latest Social Stream


Loading social stream, please wait...

View Full CNTG Social Stream

Latest CNTG News From Around the Web

Below are the latest news stories about Centogene NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.

CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company’s Annual General Meeting. The shareholders of the Company voted in favor of all proposals, which included the appointment of Rene Just as Chief Financial Officer and Managing Director of the company, as well as the

Yahoo | June 25, 2021

DGAP-News: CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years

DGAP-News: Centogene NV / Key word(s): Miscellaneous CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years 22.06.2021 / 12:30 The issuer is solely responsible for the content of this announcement. PRESS RELEASE CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within

Wallstreet:Online | June 22, 2021

CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years

Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event

Intrado Digital Media | June 22, 2021

DGAP-News: Centogene NV: CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years

DGAP-News: Centogene NV / Key word(s): Miscellaneous CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years 22.06.2021 / 12:30 The issuer is solely responsible for

FinanzNachrichten | June 22, 2021

Hereditary Cancer Testing Market Shoot Up to US$ 9,840.52 Mn Revenue by 2027 with Business Market Insights: Cancer Genetics Inc., Invitae Corporation, Myogenes, Strand Life Sciences Pvt. Ltd., Pathway Genomics Corporation, CENTOGENE AG

The Hereditary Cancer Testing Market is US$ 3,967.74 Mn in 2018 and is predicted to grow at a CAGR of 11.1% during the forecast period 2019 2027, to reach US$ 9,840.52 Mn by 2027. The market for hereditary cancer testing

OpenPR | June 21, 2021

Read More 'CNTG' Stories Here

CNTG Price Returns

1-mo 3.94%
3-mo 14.56%
6-mo -1.82%
1-year -10.79%
3-year N/A
5-year N/A
YTD 5.10%
2020 7.05%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8977 seconds.